TY - JOUR
T1 - Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment
AU - Herukka, Sanna-Kaisa
AU - Simonsen, Anja Hviid
AU - Andreasen, Niels
AU - Baldeiras, Ines
AU - Bjerke, Maria
AU - Blennow, Kaj
AU - Engelborghs, Sebastiaan
AU - Frisoni, Giovanni B
AU - Gabryelewicz, Tomasz
AU - Galluzzi, Samantha
AU - Handels, Ron
AU - Kramberger, Milica G
AU - Kulczyńska, Agnieszka
AU - Molinuevo, Jose Luis
AU - Mroczko, Barbara
AU - Nordberg, Agneta
AU - Oliveira, Catarina Resende
AU - Otto, Markus
AU - Rinne, Juha O
AU - Rot, Uroš
AU - Saka, Esen
AU - Soininen, Hilkka
AU - Struyfs, Hanne
AU - Suardi, Silvia
AU - Visser, Pieter Jelle
AU - Winblad, Bengt
AU - Zetterberg, Henrik
AU - Waldemar, Gunhild
N1 - Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.
PY - 2017
Y1 - 2017
N2 - This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β1-42, tau, and phosphorylated tau in the diagnostic evaluation of patients with mild cognitive impairment (MCI). The recommendations were developed by a multidisciplinary working group and based on the available evidence and consensus from focused group discussions for 1) prediction of clinical progression to Alzheimer's disease (AD) dementia, 2) cost-effectiveness, 3) interpretation of results, and 4) patient counseling. The working group recommended using CSF AD biomarkers in the diagnostic workup of MCI patients, after prebiomarker counseling, as an add-on to clinical evaluation to predict functional decline or conversion to AD dementia and to guide disease management. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Furthermore, the working group provided recommendations for interpretation of ambiguous CSF biomarker results and for pre- and post-biomarker counseling.
AB - This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β1-42, tau, and phosphorylated tau in the diagnostic evaluation of patients with mild cognitive impairment (MCI). The recommendations were developed by a multidisciplinary working group and based on the available evidence and consensus from focused group discussions for 1) prediction of clinical progression to Alzheimer's disease (AD) dementia, 2) cost-effectiveness, 3) interpretation of results, and 4) patient counseling. The working group recommended using CSF AD biomarkers in the diagnostic workup of MCI patients, after prebiomarker counseling, as an add-on to clinical evaluation to predict functional decline or conversion to AD dementia and to guide disease management. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Furthermore, the working group provided recommendations for interpretation of ambiguous CSF biomarker results and for pre- and post-biomarker counseling.
KW - Alzheimer Disease/cerebrospinal fluid
KW - Amyloid beta-Peptides/cerebrospinal fluid
KW - Biomarkers/cerebrospinal fluid
KW - Cognitive Dysfunction/diagnosis
KW - Humans
KW - MEDLINE/statistics & numerical data
KW - Peptide Fragments/cerebrospinal fluid
KW - tau Proteins/cerebrospinal fluid
U2 - 10.1016/j.jalz.2016.09.009
DO - 10.1016/j.jalz.2016.09.009
M3 - Scientific review
C2 - 28341066
VL - 13
SP - 285
EP - 295
JO - Alzheimer's & Dementia
JF - Alzheimer's & Dementia
SN - 1552-5260
IS - 3
ER -